Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Complement Altern Med ; 17(1): 356, 2017 Jul 06.
Article in English | MEDLINE | ID: mdl-28683738

ABSTRACT

BACKGROUND: Sarcopoterium spinosum (S. spinosum) is used by Bedouin medicinal practitioners for the treatment of diabetes. While the anti-diabetic activity of S. spinosum root extract was validated in previous studies, the activity of aerial parts of the same plants has not been elucidated yet. The aim of this study was to clarify the glucose lowering properties of the aerial parts of the shrub. METHODS: Anti-diabetic properties were evaluated by measuring the activity of carbohydrate digesting enzymes, glucose uptake into 3 T3-L1 adipocytes, and insulin secretion. Insulin signaling cascade was followed in L6 myotubes using Western blot and PathScan analysis. RESULTS: Activity of α-amylase and α-glucosidase was inhibited by extracts of all S. spinosum organs. Basal and glucose-induced insulin secretion was measured in Min6 cells and found to be enhanced as well. Glucose uptake was induced by all S. spinosum extracts, with roots found to be the most effective and fruits the least. The effect of S. spinosum on Akt phosphorylation was minor compared to insulin effect. However, GSK3ß and PRAS40, which are downstream elements of the insulin cascade, were found to be highly phosphorylated by S. spinosum extracts. Inhibition of PI3K and Akt, but not AMPK and ERK, abrogated the induction of glucose uptake by the aerial parts of the shrub. CONCLUSION: The aerial organs of S. spinosum have anti-diabetic properties and may be used as a basis for the development of dietary supplements or to identify new agents for the treatment of type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Plant Components, Aerial/chemistry , Plant Extracts/administration & dosage , Rosaceae/chemistry , 3T3-L1 Cells , Adipocytes/drug effects , Adipocytes/metabolism , Animals , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/metabolism , Enzyme Inhibitors/administration & dosage , Humans , Insulin/metabolism , Mice , alpha-Amylases/metabolism , alpha-Glucosidases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...